We are looking for novel ways to design new drugs and precise mechanisms,
Used to improve the lives of the most difficult cancer patients.

Making the World's
Leading Innovative Medicine
Accessible to Cancer Patients

We are looking for novel ways to design new drugs and precise mechanisms,
Used to improve the lives of the most difficult cancer patients.

Making the World's
Leading Innovative Medicine
Accessible to Cancer Patients

Advantage

Angel Pharmaceuticals with the mission to bring innovative quality medicines to Chinese patients to have a long-term, positive impact on society. We have brought together a local team that is aligned with this mission and that is very experienced in the Chinese market, including expertise in research and development, clinical operations and regulatory affairs, business development, and intellectual property protection.

World-class R&D

Sustainable Innovation

Patients Affordable

Pipeline：Ciforadenant （CPI-444）

Antagonist of adenosine A2A receptor

Indications：Renal cancer and Multiple myeloma

Ciforadenant is one of our main projects and is an oral small molecule antagonist of the adenosine A2A receptor. By precisely targeting and blocking A2A receptors on immune cells, ciforadenant may unleash their cancer-killing properties.

Ciforadenant is designed to block adenosine in the tumor microenvironment to bind to A2A receptors, so that the tumor lose the function of avoiding the attack by the immune system. Results from several pre-clinical models and human clinical trials have demonstrated that ciforadenant was active alone in patients with some cancers. Pre-clinical research results have been published in some famous journals and Clinical data have been presented at several conferences, including American Society of Clinical Oncology, American Cancer Research Association and Cancer Immunotherapy Association.

Pipeline：CPI-006

Anti-CD73Inhibitor of Adenosine production, anti-CD73 antibody

Indications：Solid tumors

CPI-006 is a humanized anti-73 monoclonal antibody. Unlike most antibodies, CPI-006 is a designed smart antibody and has other distinct properties: to enhance the activity and trafficking capacity of immune cells, to further reduce the destructive capabilities of cancer cells.

CPI-006 binds to CD73 and appears to inhibit production of immunosuppressive adenosine of tumor cells. It also acts on other important immune procedures.

Pipeline：CPI-818

ITK Inhibitor

Indications：T cell lymphoma and Autoimmune lymphoproliferative disorders

CPI-818 is an oral, small molecule drug and selectively inhibits ITK (interleukin-2-inducible T cell kinase). ITK is an enzyme expressed predominantly in T cells and that plays a role in T cell and natural killer (NK) cell lymphomas and leukemias, as well as in normal immune function.

Our CPI-818 has dual properties: to block malignant T cell growth, and to modulate immune responses. We believe inhibiting ITK may be of therapeutic benefit for patients with T-cell lymphomas, certain B cell lymphomas and those with solid tumors because of its potential immune-enhancing properties.

Pipeline：BTK inhibitor

3rd generation BTK inhibitor

Indications： B cell lymphoma and autoimmune disease

Compared with 1st generation BTK inhibitor, Ibrutinib, 3rd generation BTK inhibitor has higher selectivity and increases the permeability of blood-brain barrier. It is expected to have better efficacy in the treatment of central nervous system lymphoma and other B-cell lymphoma.

{label:enzhejiang}

{label:enbeijing}

{label:enshanghai}

{label:enusa}

For more information, please contact：IR@angelpharma.com

866 Malcolm Road, Burlingame, California 94010, USA

15C8, 15F, Building T2, Xihuan Plaza, Xicheng District, Beijing, PRC

701, D-3, Hongqiao World Center, Qingpu District, Shanghai, PRC

6F, Zhejiang Future Technology Institute, Nanhu District, Jiaxing, Zhejiang, PRC

For more information, please contact：IR@angelpharma.com

Making the World'sLeading Innovative MedicineAccessible to Cancer Patients

Making the World'sLeading Innovative MedicineAccessible to Cancer Patients

Advantage

Antagonist of adenosine A2A receptor

Anti-CD73Inhibitor of Adenosine production, anti-CD73 antibody

ITK Inhibitor

3rd generation BTK inhibitor

Making the World's
Leading Innovative Medicine
Accessible to Cancer Patients

Making the World's
Leading Innovative Medicine
Accessible to Cancer Patients